42 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b … cyclophosphamide at 60 mg/kg/day for 2 days, then fludarabine at 25 mg/m2/day for 5 days. The objectives of our ANTLER trial include the assessment
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
DAYS Safety and tolerability Response assessment Treatment and objective Primary endpoint: safety Eligibility and matching Cohort 1: Lupus nephritis (LN
8-K
EX-1.1
3um9dsql mc1
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
244qr0gvz51autdeams
14 Jul 23
Prospectus supplement for primary offering
5:31pm
8-K/A
EX-99.1
dm0syhf67xl22
14 Jul 23
Other Events
4:22pm
424B5
f3am62k
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-99.2
28n1xq7501j0q
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
8-K
EX-99.1
ni6yknqtf1w
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
8-K
EX-99.1
spqakpal
13 Jul 23
Other Events
4:17pm
8-K
EX-10.1
z9xygalpi2jk
6 Jul 23
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
8:01am
ARS
rw6i yu6cgeq33u
28 Apr 23
Annual report to shareholders
12:00am
DEF 14A
231wc3fl4udout
11 Aug 22
Definitive proxy
4:04pm
S-3
EX-1.2
yp8egg na37xxri82x
9 Aug 22
Shelf registration
12:00am